TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Perioperative Administration of Pregabalin for Pain After Mastectomy
Brief Summary: The investigators hypothesize that pregabalin will decrease post-operative pain scores and analgesic use following total mastectomy compared to placebo. The primary outcome will be acute postoperative pain, measured by a verbal numerical rating score (VNRS) and total analgesic consumption during postoperative 48 hours. The secondary outcome will be VNRS at 1 week and 1 month after operation.


Options:
A: Arm Label: Gabapentin preoperatively; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Active placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Diphenhydramine | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin preoperatively | Intervention Type: DRUG; Name: Diphenhydramine; Assigned to Arm(s): Active placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Intervention Type: PROCEDURE; Name: perioperative epidural catheter; Assigned to Arm(s): 1, 2, 3, 4, 5
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin Complex (placebo) | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Vitamin Complex (placebo); Assigned to Arm(s): Placebo
D: Arm Label: morphine only; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine | Arm Label: morphine ketamine; Type: EXPERIMENTAL; Interventions: Drug: morphine ketamine | Intervention Type: DRUG; Name: morphine; Assigned to Arm(s): morphine only | Intervention Type: DRUG; Name: morphine ketamine; Assigned to Arm(s): morphine ketamine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antenatal Vitamin D Supplementation to Improve Neonatal Health Outcomes in Dhaka, Bangladesh: Preliminary Dose-finding and Safety Study
Brief Summary: This is a preliminary study of oral vitamin D3 supplementation in pregnant and non-pregnant women of reproductive age in Bangladesh. The primary objective of the study is to identify a dose of vitamin D3 that can safely be administered during pregnancy to improve the vitamin D status of the mother and infant.


Options:
A: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo tablet | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol D3; Assigned to Arm(s): Vitamin D | Intervention Type: OTHER; Name: Placebo tablet; Assigned to Arm(s): Placebo
B: Arm Label: A1 - non-pregnant single-dose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: A2 - non-pregnant; weekly dose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: B1 - pregnant; single-dose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: B2 - pregnant; weekly dose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: C1 - active control; pregnant women; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): A1 - non-pregnant single-dose, B1 - pregnant; single-dose | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): A2 - non-pregnant; weekly dose, B2 - pregnant; weekly dose | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): C1 - active control; pregnant women
C: Arm Label: 400 IU Vitamin D3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 400 IU vitamin D3 | Arm Label: 2,000 IU Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 2,000 IU Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 400 IU vitamin D3; Assigned to Arm(s): 400 IU Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 2,000 IU Vitamin D3; Assigned to Arm(s): 2,000 IU Vitamin D3
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: Calcium plus vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Calcium plus vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium plus vitamin D; Assigned to Arm(s): Calcium plus vitamin D

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study To Investigate the Safety and Tolerability of YM150 in Subjects With Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability With Warfarin
Brief Summary: The purpose of this study is to investigate the optimal daily dose and dose regimen of YM150 in subjects with non-valvular atrial fibrillation (NVAF), primarily based on safety and tolerability data.


Options:
A: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Placebo (for warfarin), Drug: Avidin | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Placebo (for idrabiotaparinux), Drug: Placebo (for avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for idrabiotaparinux); Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Placebo (for warfarin); Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for avidin); Assigned to Arm(s): Warfarin
B: Arm Label: Apixaban 5mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Apixaban 2.5mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin sodium | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban 5mg BID | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban 2.5mg BID | Intervention Type: DRUG; Name: Warfarin sodium; Assigned to Arm(s): Warfarin
C: Arm Label: 1. YM150, Dose W, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 2. YM150, Dose X, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 3. YM150, Dose X, twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 4. YM150, Dose Y once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 5. YM150, Dose Y twice daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 6. YM150, Dose Z, once daily; Type: EXPERIMENTAL; Interventions: Drug: YM150 | Arm Label: 7. Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: YM150; Assigned to Arm(s): 1. YM150, Dose W, twice daily, 2. YM150, Dose X, once daily, 3. YM150, Dose X, twice daily, 4. YM150, Dose Y once daily, 5. YM150, Dose Y twice daily, 6. YM150, Dose Z, once daily | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): 7. Warfarin
D: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Acetylasalicylic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Acetylasalicylic acid

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhanced Self-Efficacy Training For Informal Cancer Caregivers
Brief Summary: The goal of this study is to examine the effects of an enhanced caregiver training protocol that not only teaches informal caregivers knowledge and skills for managing patient symptoms, but also provides strategies for managing their own psychological distress. The investigators anticipate this training will increase caregivers' self-efficacy and improve important caregiver outcomes (depression, anxiety, burden, quality of life) and patient outcomes (symptom distress/intensity, depression, anxiety, and quality of life). The study will compare the effects of this protocol to an education control condition that equates for interventionist time and attention.


Options:
A: Arm Label: Self-Efficacy Training for Caregivers; Type: OTHER; Interventions: Other: Self-Efficacy Training for Caregivers | Arm Label: Comparison Conditions for Caregivers; Type: OTHER; Interventions: Other: Comparison Conditions for Caregivers | Intervention Type: OTHER; Name: Self-Efficacy Training for Caregivers; Assigned to Arm(s): Self-Efficacy Training for Caregivers | Intervention Type: OTHER; Name: Comparison Conditions for Caregivers; Assigned to Arm(s): Comparison Conditions for Caregivers
B: Arm Label: Psycho-educational support group therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psycho-educational support group therapy | Intervention Type: BEHAVIORAL; Name: Psycho-educational support group therapy; Assigned to Arm(s): Psycho-educational support group therapy
C: Arm Label: Experimental: supportive care; Type: EXPERIMENTAL; Interventions: Other: Supportive care | Arm Label: Control: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Supportive care; Assigned to Arm(s): Experimental: supportive care
D: Arm Label: Nueva Vida Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nueva Vida Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nueva Vida Intervention; Assigned to Arm(s): Nueva Vida Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Based Obesity Prevention Among Blacks
Brief Summary: The purpose of this study is to examine whether pedometer step count recommendations (10,000 steps/day versus an adaptive recommendation) are differentially associated with the primary outcome of adherence to the pedometer-based physical activity regimen and the secondary outcomes of change in physical activity and body mass index (BMI).


Options:
A: Arm Label: Intervention for diet, exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational intervention for diet and physical activity | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Educational message on skin cancer awareness | Intervention Type: BEHAVIORAL; Name: Educational intervention for diet and physical activity; Assigned to Arm(s): Intervention for diet, exercise | Intervention Type: BEHAVIORAL; Name: Educational message on skin cancer awareness; Assigned to Arm(s): Control
B: Arm Label: 10,000 step/day recommendation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 10,000 step/day recommendation | Arm Label: Adaptive recommendation; Type: EXPERIMENTAL; Interventions: Behavioral: Adaptive step recommendation | Intervention Type: BEHAVIORAL; Name: Adaptive step recommendation; Assigned to Arm(s): Adaptive recommendation | Intervention Type: BEHAVIORAL; Name: 10,000 step/day recommendation; Assigned to Arm(s): 10,000 step/day recommendation
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mini Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Mini Booster | Arm Label: Full Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Full Booster | Intervention Type: BEHAVIORAL; Name: Mini Booster; Assigned to Arm(s): Mini Booster | Intervention Type: BEHAVIORAL; Name: Full Booster; Assigned to Arm(s): Full Booster
D: Arm Label: Facebook and Text Message; Type: EXPERIMENTAL; Interventions: Behavioral: Facebook and text Message | Arm Label: Standard Print-based Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Print-based Intervention | Intervention Type: BEHAVIORAL; Name: Facebook and text Message; Assigned to Arm(s): Facebook and Text Message | Intervention Type: BEHAVIORAL; Name: Standard Print-based Intervention; Assigned to Arm(s): Standard Print-based Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index: A Prospective Multicenter Study
Brief Summary: Eosinophilic Esophagitis (EoE) is a chronic inflammatory disease of the esophagus affecting children and adults. The most frequent symptoms are swallowing difficulties and thoracic pain. The disease has first been described in the 1980s and is found with rapidly increasing frequency mainly in industrialized countries. The factors that lead to EoE are until now incompletely understood, of importance, the disease is found more frequently in men and patients suffering from allergic diseases (e.g., Asthma). So far there exists no activity index to define the severity of EoE; such an index is urgently needed for future clinical trials to determine the efficacy of current and future therapies. The investigators' 3-year project, carried out in cooperation with international EoE experts, aims at the development of an activity index for adult and pediatric EoE patients that will be used in future clinical trials as well as observational studies.


Options:
A: Arm Label: 1; Type: N/A; Interventions: Other: assessment of disease activity using the EEsAI | Arm Label: 2; Type: N/A; Interventions: Other: assessment of disease activity using the EEsAI | Intervention Type: OTHER; Name: assessment of disease activity using the EEsAI; Assigned to Arm(s): 1, 2
B: Intervention Type: DRUG; Name: mepolizumab; Assigned to Arm(s): N/A
C: Arm Label: Low dose budesonide tablet; Type: EXPERIMENTAL; Interventions: Drug: low dose budesonide tablet | Arm Label: High dose budesonide tablet; Type: EXPERIMENTAL; Interventions: Drug: high dose budesonide tablet | Arm Label: High dose budesonide suspension; Type: EXPERIMENTAL; Interventions: Drug: high dose budesonide suspension | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: low dose budesonide tablet; Assigned to Arm(s): Low dose budesonide tablet | Intervention Type: DRUG; Name: high dose budesonide tablet; Assigned to Arm(s): High dose budesonide tablet | Intervention Type: DRUG; Name: high dose budesonide suspension; Assigned to Arm(s): High dose budesonide suspension | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Mometasone furoat; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate | Arm Label: Placebo spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate; Assigned to Arm(s): Mometasone furoat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo spray

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate NEVANAC in patients with diabetic retinopathy who developed macular edema (ME) within 90 days following cataract surgery.


Options:
A: Arm Label: NEVANAC; Type: EXPERIMENTAL; Interventions: Drug: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®) | Arm Label: Nepafenac Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nepafenac ophthalmic suspension vehicle | Intervention Type: DRUG; Name: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®); Assigned to Arm(s): NEVANAC | Intervention Type: DRUG; Name: Nepafenac ophthalmic suspension vehicle; Assigned to Arm(s): Nepafenac Vehicle
B: Arm Label: Nepafenac; Type: EXPERIMENTAL; Interventions: Drug: Nepafenac | Arm Label: Ketorolac; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketorolac | Intervention Type: DRUG; Name: Nepafenac; Assigned to Arm(s): Nepafenac | Intervention Type: DRUG; Name: Ketorolac; Assigned to Arm(s): Ketorolac
C: Arm Label: NEVANAC; Type: EXPERIMENTAL; Interventions: Drug: Nepafenac ophthalmic suspension, 0.1% (NEVANAC), Drug: Prednisolone acetate ophthalmic suspension (OMNIPRED) | Arm Label: Nepafenac Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Other: Nepafenac ophthalmic suspension vehicle, Drug: Prednisolone acetate ophthalmic suspension (OMNIPRED) | Intervention Type: DRUG; Name: Nepafenac ophthalmic suspension, 0.1% (NEVANAC); Assigned to Arm(s): NEVANAC | Intervention Type: OTHER; Name: Nepafenac ophthalmic suspension vehicle; Assigned to Arm(s): Nepafenac Vehicle | Intervention Type: DRUG; Name: Prednisolone acetate ophthalmic suspension (OMNIPRED); Assigned to Arm(s): NEVANAC, Nepafenac Vehicle
D: Intervention Type: DRUG; Name: Ketorolac, Prednisolone Acetate; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy (SMART) in Asthma Patients Across Asia: SMARTASIA
Brief Summary: The purpose of this study is to compare whether Symbicort Maintenance \& Reliever Therapy (SMART) is more effective in uncontrolled asthmatic patients than their current therapy in a real life situation.


Options:
A: Intervention Type: DRUG; Name: beclomethasone/salbutamol combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beclomethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort (Budesonide/Formoterol) | Intervention Type: DRUG; Name: Symbicort (Budesonide/Formoterol); Assigned to Arm(s): 1
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: salbutamol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): 2
D: Arm Label: Mometasone then Tiotropium then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Mometasone 220mcg BID, Drug: Tiotropium Respimat 5mcg QD, Drug: Placebo | Arm Label: Mometasone then Placebo then Tiotropium; Type: EXPERIMENTAL; Interventions: Drug: Mometasone 220mcg BID, Drug: Tiotropium Respimat 5mcg QD, Drug: Placebo | Arm Label: Placebo then Mometasone then Tiotropium; Type: EXPERIMENTAL; Interventions: Drug: Mometasone 220mcg BID, Drug: Tiotropium Respimat 5mcg QD, Drug: Placebo | Arm Label: Placebo then Tiotropium then Mometasone; Type: EXPERIMENTAL; Interventions: Drug: Mometasone 220mcg BID, Drug: Tiotropium Respimat 5mcg QD, Drug: Placebo | Arm Label: Tiotropium then Placebo then Mometasone; Type: EXPERIMENTAL; Interventions: Drug: Mometasone 220mcg BID, Drug: Tiotropium Respimat 5mcg QD, Drug: Placebo | Arm Label: Tiotropium then Mometasone then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Mometasone 220mcg BID, Drug: Tiotropium Respimat 5mcg QD, Drug: Placebo | Intervention Type: DRUG; Name: Mometasone 220mcg BID; Assigned to Arm(s): Mometasone then Placebo then Tiotropium, Mometasone then Tiotropium then Placebo, Placebo then Mometasone then Tiotropium, Placebo then Tiotropium then Mometasone, Tiotropium then Mometasone then Placebo, Tiotropium then Placebo then Mometasone | Intervention Type: DRUG; Name: Tiotropium Respimat 5mcg QD; Assigned to Arm(s): Mometasone then Placebo then Tiotropium, Mometasone then Tiotropium then Placebo, Placebo then Mometasone then Tiotropium, Placebo then Tiotropium then Mometasone, Tiotropium then Mometasone then Placebo, Tiotropium then Placebo then Mometasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Mometasone then Placebo then Tiotropium, Mometasone then Tiotropium then Placebo, Placebo then Mometasone then Tiotropium, Placebo then Tiotropium then Mometasone, Tiotropium then Mometasone then Placebo, Tiotropium then Placebo then Mometasone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Phase II Trial of Cediranib (AZD2171) Versus Placebo in Addition to Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers
Brief Summary: As a result of our previous NCRN study (ABC-02) cisplatin and gemcitabine (CisGem) is likely to become the international standard of care for patients with advanced biliary tract cancer (submitted: ASCO 2009).

This study, ABC-03, will determine whether the addition of cediranib(an oral Vascular Endothelial Growth Factor Receptor inhibitor) to CisGem will improve the time to disease progression in this patient group.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: ZD6474, Vandetanib | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: ZD6474, Vandetanib, Drug: Gemcitabine | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Placebo matching ZD6474 | Intervention Type: DRUG; Name: ZD6474, Vandetanib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ZD6474, Vandetanib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): B, C | Intervention Type: DRUG; Name: Placebo matching ZD6474; Assigned to Arm(s): C
B: Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: cediranib, Drug: gemcitabine | Arm Label: Arm A; Type: PLACEBO_COMPARATOR; Interventions: Drug: gemcitabine, Drug: cisplatin, Drug: Placebo | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: cediranib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): B
C: Arm Label: GEMOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine, oxaliplatin | Arm Label: E-GEMOX; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, gemcitabine, oxaliplatin | Intervention Type: DRUG; Name: gemcitabine, oxaliplatin; Assigned to Arm(s): GEMOX | Intervention Type: DRUG; Name: cetuximab, gemcitabine, oxaliplatin; Assigned to Arm(s): E-GEMOX
D: Arm Label: SP treatment; Type: EXPERIMENTAL; Interventions: Drug: S-1 plus cisplatin | Arm Label: GP treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine plus Cisplatin | Intervention Type: DRUG; Name: S-1 plus cisplatin; Assigned to Arm(s): SP treatment | Intervention Type: DRUG; Name: Gemcitabine plus Cisplatin; Assigned to Arm(s): GP treatment

Answer: B